Year in Review: Updates in Antibody-Drug Conjugates for Treating Advanced NSCLC

Shirish Gadgeel, MD, and Benjamin Levy, MD, discuss recent updates in 2023 on antibody-drug conjugates for treating patients with advanced NSCLC as well as their clinical implications.

EP. 1: Molecular Testing in Advanced NSCLC

January 18th 2024

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

EP. 2: T-DXd in HER2 Mutated Advanced NSCLC

January 22nd 2024

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

EP. 3: Dato-DXd for Treating Advanced NSCLC

January 26th 2024

Benjamin Levy, MD, reviews clinical data on Dato-DXd in patients with advanced NSCLC and their practical implications.

EP. 4: Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC

February 6th 2024

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

EP. 5: Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC

February 9th 2024

Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

EP. 6: Future Perspectives in ADCs for Treating Advanced NSCLC

February 12th 2024

Dr. Shirish Gadgeel discusses the activity of antibody drug conjugates against brain metastases in non-small cell lung cancer based on emerging data, suggesting superiority over chemotherapy.

EP. 7: Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC

February 26th 2024

Benjamin Philip Levy, MD, details how antibody-drug conjugates are shifting the HER2-mutated non–small cell lung cancer treatment paradigm.

EP. 8: Increasingly Targeted ADCs Drive NSCLC Treatment Innovations

April 12th 2024

Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.